AU4510596A - Water soluble ubiquinone compositions, prodrugs, and methods relating thereto - Google Patents

Water soluble ubiquinone compositions, prodrugs, and methods relating thereto

Info

Publication number
AU4510596A
AU4510596A AU45105/96A AU4510596A AU4510596A AU 4510596 A AU4510596 A AU 4510596A AU 45105/96 A AU45105/96 A AU 45105/96A AU 4510596 A AU4510596 A AU 4510596A AU 4510596 A AU4510596 A AU 4510596A
Authority
AU
Australia
Prior art keywords
prodrugs
compositions
water soluble
methods relating
soluble ubiquinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45105/96A
Inventor
Henryk Borowy-Borowski
Scott S Graves
A. Charles Morgan
Marianna Sikorska
Roy Walker
D. Scott Wilbur
Clive S. Woodhouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RYAN PHARMACEUTICALS Inc
National Research Council of Canada
University of Washington
Original Assignee
RYAN PHARMACEUTICALS Inc
National Research Council of Canada
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RYAN PHARMACEUTICALS Inc, National Research Council of Canada, University of Washington filed Critical RYAN PHARMACEUTICALS Inc
Publication of AU4510596A publication Critical patent/AU4510596A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU45105/96A 1994-12-06 1995-12-06 Water soluble ubiquinone compositions, prodrugs, and methods relating thereto Abandoned AU4510596A (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US35022094A 1994-12-06 1994-12-06
US350220 1994-12-06
US48697395A 1995-06-07 1995-06-07
US48421395A 1995-06-07 1995-06-07
US48471895A 1995-06-07 1995-06-07
US48840095A 1995-06-07 1995-06-07
US48545095A 1995-06-07 1995-06-07
US48060695A 1995-06-07 1995-06-07
US488400 1995-06-07
US485450 1995-06-07
US486973 1995-06-07
US480606 1995-06-07
US484213 1995-06-07
US484718 1995-06-07
PCT/US1995/015888 WO1996017626A2 (en) 1994-12-06 1995-12-06 Water soluble ubiquinone compositions, prodrugs, and methods relating thereto

Publications (1)

Publication Number Publication Date
AU4510596A true AU4510596A (en) 1996-06-26

Family

ID=27569706

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45105/96A Abandoned AU4510596A (en) 1994-12-06 1995-12-06 Water soluble ubiquinone compositions, prodrugs, and methods relating thereto

Country Status (5)

Country Link
EP (1) EP0796108A2 (en)
JP (1) JPH10509732A (en)
AU (1) AU4510596A (en)
CA (1) CA2207093A1 (en)
WO (1) WO1996017626A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3889481B2 (en) * 1996-08-16 2007-03-07 株式会社カネカ Pharmaceutical composition
IT1290907B1 (en) * 1997-01-31 1998-12-14 Idi Farmaceutici Spa COMPOSITION BY DIET PRODUCT EFFECTIVE IN COMBATING OXIDATIVE STRESS AND CELL DECAY.
US6544797B1 (en) 1997-04-09 2003-04-08 Biosite Diagnostics, Inc. Compositions and methods for inhibiting light-induced inactivation of biological reagents
DE19905880A1 (en) * 1999-02-11 2000-08-17 Mse Pharmazeutika Gmbh Spray containing ubiquinone Qn
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) * 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
WO2001034093A2 (en) * 1999-11-09 2001-05-17 Hybridon, Inc. Potentiation of prodrug efficacy
US6864231B2 (en) 2001-01-09 2005-03-08 Pharmachem Laboratories, Inc. Glycoprotein matrix compositions and methods related thereto
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
TWI237018B (en) * 2001-07-13 2005-08-01 Kaneka Corp Method of producing reduced coenzyme Q10 crystals
CN100503543C (en) * 2001-07-13 2009-06-24 钟渊化学工业株式会社 Method of producing reduced coenzyme q10 as oily product
TWI310029B (en) * 2001-07-13 2009-05-21 Kaneka Corp
TW200604159A (en) * 2001-07-13 2006-02-01 Kaneka Corp Method of producing reduced coenzyme Q10 as oily product
TWI235146B (en) 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
ITRM20010755A1 (en) 2001-12-20 2003-06-20 Simonelli Giuseppe USE OF Q10 QUINONE FOR THE TREATMENT OF EYE DISEASES.
TWI305547B (en) 2001-12-27 2009-01-21 Kaneka Corp Processes for producing coenzyme q10
WO2004063131A1 (en) * 2003-01-10 2004-07-29 Kaneka Corporation Method of purifying reduced coenzyme q
AU2004251602B2 (en) * 2003-05-23 2010-05-13 Nektar Therapeutics PEG derivatives having an amidocarbonate linkage
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
CA2549011A1 (en) * 2003-12-10 2005-06-30 Nektar Therapeutics Al, Corporation Compositions comprising two different populations of polymer-active agent conjugates
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US20070203080A1 (en) * 2006-02-15 2007-08-30 The Regents Of The University Of California New Drug Delivery System for Crossing the Blood Brain Barrier
JP5180556B2 (en) 2006-10-13 2013-04-10 昭和電工株式会社 Skin external preparations and cosmetics containing ubiquinone derivatives or salts thereof, and methods of use thereof
US20080233056A1 (en) * 2007-03-19 2008-09-25 Zymes, Llc Organoleptic compounds with enhanced properties
US8454945B2 (en) 2007-03-22 2013-06-04 Berg Pharma Llc Topical formulations having enhanced bioavailability
WO2008134766A1 (en) * 2007-04-30 2008-11-06 Zymes, Llc Applications of ubiquinones and ubiquinols
EP3015104A1 (en) 2008-04-11 2016-05-04 Berg LLC Methods and use of inducing apoptosis in cancer cells
SG10201402289VA (en) 2009-05-11 2014-07-30 Berg Llc Methods for treatment of disease using an epimetabolic shifter (coenzyme q10)
US8927043B2 (en) 2009-11-10 2015-01-06 Mycell Technologies Stabilized formulations of fatty acids
CA2791693C (en) 2010-03-12 2018-11-27 Niven Rajin Narain Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
KR101933732B1 (en) 2011-04-04 2018-12-28 버그 엘엘씨 Methods of treating central nervous system tumors
KR102058256B1 (en) 2011-06-17 2020-01-22 버그 엘엘씨 Inhalable pharmaceutical compositions
CN104903289B (en) * 2012-12-03 2017-06-09 株式会社钟化 Also first type ubiquinone10Derivative and its manufacture method
EP2983654A4 (en) 2013-04-08 2016-11-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
NZ717504A (en) 2013-09-04 2022-07-01 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
MA47328A (en) 2017-10-24 2019-05-01 Difass Int S R L COMPOSITION CONSISTING OF COENZYME Q10 AND PIPERINE
EP3820452A1 (en) 2018-07-09 2021-05-19 Volker Berl Stabilized formulations of cannabinoid compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6020368B2 (en) * 1974-10-11 1985-05-21 エーザイ株式会社 Production method of 1,4 benzohydroquinone derivative
CA1091680A (en) * 1976-10-19 1980-12-16 Shinji Terao Method for production of quinones
JPS54160327A (en) * 1978-06-06 1979-12-19 Kuraray Co Ltd Preparation of coenzyme q
JPS5564538A (en) * 1978-11-06 1980-05-15 Ajinomoto Co Inc Preparation of dihydrocoenzyme q compound
JPS60255749A (en) * 1984-05-31 1985-12-17 Univ Nagoya Quinone derivative
IL78611A0 (en) * 1986-04-23 1986-08-31 Yeda Res & Dev Production of polyprenoid and ubiquinone-type compounds

Also Published As

Publication number Publication date
JPH10509732A (en) 1998-09-22
WO1996017626A2 (en) 1996-06-13
EP0796108A2 (en) 1997-09-24
CA2207093A1 (en) 1996-06-13
WO1996017626A3 (en) 1996-08-29

Similar Documents

Publication Publication Date Title
AU4510596A (en) Water soluble ubiquinone compositions, prodrugs, and methods relating thereto
AU4677397A (en) New alpha-aminoacetophenone photoinitiators
AU3345195A (en) Surface-active formulations
AU3345295A (en) Surface-active formulations
AU4984497A (en) Germicidal composition
AU7179098A (en) Flow form
AU2681895A (en) 8-aryl-1,6-naphthyridin-5-ones
AU1655795A (en) Non-sensitizing biocide compositions
AU5157898A (en) Hnf3delta compositions
AU3701397A (en) Anti-herpesviral agent
AUPM896094A0 (en) Water turbine
AU1740495A (en) Limescale removing compositions
AU5334198A (en) Face masks
AU4384297A (en) Antiviral compositions
AU1509095A (en) Plant disease-controlling agent
AU3771495A (en) Rotatable scaffold
AU4598297A (en) Soaker compositions
AU1738497A (en) Lockable coupling
AUPM661094A0 (en) Improved clipon ct
AU4415897A (en) Phenolic stain-resists
AU3384697A (en) Diphenyl-cyclopropenes as selective k-agonists
AU6485399A (en) Ribozymes used as prodrugs
ZA978677B (en) Soaker compositions.
AU3898195A (en) Cultivator
AUPM664294A0 (en) Cultivator